Drug Profile
Research programme: single chain antibody fragment fusion proteins - Targa Therapeutics
Alternative Names: BreMel/rGel; BreMel/TNFα; scFv23/rGel; scFvMel/rGel; scFvMEL/TNFαLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Targa Therapeutics Corporation
- Class Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants; N-glycosyl hydrolase inhibitors; Tumour necrosis factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Breast cancer; Malignant melanoma
Highest Development Phases
- No development reported Breast cancer; Malignant melanoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma(Prevention) in USA (Parenteral)